Last day of trading in warrants of series TO 5 B is today 24 February 2023
Lund, Sweden – Today, 24 February 2023, is the last day of trading in warrants of series TO 5 B, which were issued in connection with Clinical Laserthermia Systems AB’s ("CLS" or the "Company") rights issue of units that was announced on 10 August 2022. The exercise period runs until and including 28 February 2023.
Each warrant of series TO 5 B entitles the holder to subscribe for one (1) new B-share in CLS at a price of SEK 0.46 per share during the exercise period that started on 14 February 2023 and runs until and including 28 February 2023.
For warrants not to expire worthless, warrant holders must subscribe for new shares, with the support of warrants, at 17:00 CET on 28 February 2023, at the latest, alternatively sell warrants no later than on 24 February 2023.
For more information, including a more detailed description of CLS's operations as well as complete terms and conditions, please refer to the prospectus that was prepared in connection with the rights issue and published by the Company on 16 August 2022. The prospectus is available on CLS website (https://clinicallaser.se/wp-content/uploads/2022/08/Clinical-Laserthermia-Systems-AB-Prospekt.pdf). Information brochures containing summary information about the Company and the offer (in Swedish and English) are available on the websites of CLS (www.clinicallaser.se), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and conditions for warrants of series TO 5 B are available on the Company's website.
Advisors
In connection with the exercise of warrants of series TO 5 B, Sedermera Corporate Finance AB is acting as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB is assisting the Company with advice regarding communication.
For more information about the warrants of series TO 5 B, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
For more information about CLS, please contact:
Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se